Publicacións nas que colabora con Margarita Reboredo Lopez (8)

2021

  1. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 351-359

  2. First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study

    Journal of Geriatric Oncology, Vol. 11, Núm. 8, pp. 1263-1267

  3. First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial

    Clinical and Translational Oncology, Vol. 22, Núm. 4, pp. 495-502

2019

  1. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

    Cancer Medicine, Vol. 8, Núm. 3, pp. 882-889

2018

  1. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

    BMC Cancer, Vol. 18, Núm. 1

2013

  1. Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: A retrospective study

    Anticancer Research, Vol. 33, Núm. 9, pp. 4089-4096

2010

  1. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer

    British Journal of Cancer, Vol. 103, Núm. 10, pp. 1536-1541